Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naloxone/oxycodone - Mundipharma

Drug Profile

Naloxone/oxycodone - Mundipharma

Alternative Names: OXN PR; Oxycodone hydrochloride/naloxone hydrochloride - Mundipharma; Oxycodone/naloxone extended release - Mundipharma; Oxycodone/naloxone prolonged release - Mundipharma; Targin; Targinact; Targiniq; Targiniq ER

Latest Information Update: 15 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mundipharma GmbH
  • Developer Mundipharma GmbH; Purdue Pharma
  • Class Antidotes; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Constipation; Pain; Restless legs syndrome
  • Phase II Interstitial cystitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Jun 2018 Chemical structure information added
  • 30 Mar 2017 Mundipharma completes a phase III trial in Pain (non-cancer) in China (PO) (NCT01918098)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top